Language
CN
EN
Product pipeline
Product ID
Product
Discovery Preclinic IND Clinical
Features

DIFF-flu

Trivalent intranasal influenza vaccine for humans
FIC; M2 gene modification achieves balance between attenuation for safety and robust immunogenicity for efficacy

DIFF-OV 001

Oncolytic virus therapy for colorectal cancer
Me-better; Complete tumor eradication in mouse model with safe, potent VSV oncolytic virus

DIFF-Rab

VSV-vectored rabies vaccine for companion animals
BIC; Adjuvant-free, eliminating stress and adjuvant-related side effects

DIFF-H9N2

Live attenuated avian influenza vaccine
FIC; Needle-free spray / intranasal / eye-drop delivery reduces labor costs

DIFF-DIVA H9

Inactivated avian influenza DIVA vaccine
FIC; Versatile platform applicable to H5 and H7 avian influenza vaccines with built-in DIVA capability
  • M2-based Live Attenuated Vaccine Platform
    We pioneered a restricted-replication, M2 gene-modified influenza virus technology, which significantly reduces viral replication while maintaining immunogenicity, achieving a safer and more thorough attenuation. By modifying key regions of the M protein, viral replication in the host is limited to simulate natural infection, inducing broad and long-lasting immune responses. This platform is highly versatile and allows rapid substitution of different subtype antigens.

    Technical Advantages: All core technologies are original discoveries. We hold 8 national invention patents and 4 international patents, covering the full chain from molecular design and vector construction to production processes. This patent portfolio forms an essential barrier to entry for the industry’s use of M2-based attenuation strategies.

    Representative Projects: Intranasal live attenuated influenza vaccine (DIFF-flu); Live attenuated H9 avian influenza vaccine (DIFF-H9N2)

    Potential Applications: Universal influenza vaccines, human avian influenza vaccines, bovine influenza vaccines

  • Oncolytic Virus Platform
    We have developed a novel VSV-based oncolytic virus platform using precise genetic engineering to balance oncolytic activity with safety. Through enhanced tumor targeting and neurotoxicity elimination, this platform improves viral lysis efficiency and therapeutic specificity, offering new treatment strategies for solid tumors, particularly colorectal cancer. By optimizing key regulatory elements in the VSV genome, viral replication in normal tissues is restricted while achieving efficient replication and selective lysis in tumor cells. This selectively kills tumor cells and activates host antitumor immunity.

    Technical Advantages: Original technology; 4 national invention patents filed.

    Representative Research Achievements: Colorectal cancer is the first clinical indication. Preclinical data demonstrates significant therapeutic potential and favorable safety.

    Potential Applications: Expansion to multiple cancer types and clinical translation.

  • Recombinant Viral Vector Technology Platform
    This platform leverages VSV, NDV, and other viral vectors to construct recombinant expression systems capable of carrying multiple antigens, with high safety and immunogenicity, without including the complete pathogen genome.

    Technical Advantages: Supports multiple foreign antigens for combined prevention of multiple pathogens. We hold 16 national invention patents and 2 international patents. The mature technology allows rapid antigen replacement once the base construct is obtained, dramatically shortening development timelines.

    Representative Projects: VSV-vectored rabies vaccine for companion animals (DIFF-Rab); Recombinant NDV-vectered vaccine for SARS-CoV-2

    Potential Applications: Viral vectored vaccines, in vivo CAR-T

  • Antiviral Drug Screening Platform
    We have established a high-throughput antiviral drug screening platform based on fluorescent protein reporter systems, enabling rapid evaluation of drug activity at the cellular level. Changes in fluorescence reflect protease activity in real-time, allowing visual assessment of drug responses. Screening results directly inform molecular optimization and efficacy prediction and can be integrated with computer-aided drug design (CADD) to improve efficiency.

    Technical Advantages: Low biosafety level, high throughput, and high correlation with live-virus results. Original technology with 14 national invention patents and 1 international patent.

    Scope of Application: Chikungunya virus, Monkeypox virus, Norovirus, Herpes simplex virus, SARS-CoV-2, and other major pathogens

  • DIVA Vaccine Platform
    Our DIVA (Differentiating Infected from Vaccinated Animals) vaccine platform uses marker gene design to integrate immunization with epidemiological surveillance. By introducing specific marker genes into vaccine strains, serological tests can distinguish vaccine-induced antibodies from those generated by natural infection.

    Technical Advantages: 3 national and 9 international patents granted; awarded the China Patent Excellence Award. The technology represents the most industrially mature DIVA system in China.

    Representative Projects: Inactivated Avian Influenza DIVA Vaccine (DIFF-DIVA H9)

    Potential Applications: Avian influenza DIVA vaccines and its combined vaccines

Nasal spray attenuated influenza trivalent vaccine

Our company's nasal spray trivalent attenuated influenza vaccine is the first domestically produced human nasal spray influenza vaccine with independent intellectual property rights. This product adopts the world's first M2 gene modified attenuated technology, which has disruptive technological innovation significance and fills the gap in China's attenuated vaccine technology field. Currently, we have obtained multiple domestic and international invention patent authorizations. Our nasal spray influenza vaccine is a attenuated strain of influenza with limited replication ability, which does not rely on low-temperature conditions for replication and avoids the risk of viral mutation infection in cold air environments. The non clinical trial results indicate that the influenza vaccine developed by our company has a shorter detoxification time, lower viral load in animal tissues, fewer side effects, and higher safety and stability after intranasal administration. At the same time, it can induce multi-level immune protection including mucosal immunity, humoral immunity, and cellular immunity, covering four different subtypes of influenza A and B, with stronger protective effect, especially against heterologous influenza viruses. In addition, the production of vaccines can adopt mature chicken embryo production technology, which also brings great convenience to production practice. Our nasal spray influenza vaccine is benchmarked against the global multinational company AstraZeneca's marketed nasal spray influenza vaccine product Flumist, breaking the limitation of insufficient protection against mutant strains in current marketed influenza vaccines. We have also made new breakthroughs in broad-spectrum and safety, and are expected to solve the industry pain points of insufficient protection against seasonal influenza vaccines that require frequent research and development but insufficient mass production. The needle free design of nasal spray vaccination also provides an alternative solution for groups who are afraid of injections, especially for children. The needle free design can improve the feeling and willingness of vaccination.